Disclosed is a process for the purification of staurosporine (1), which comprises salification of staurosporine (1) (Formula (1)) by treatment with a mineral acid to give a precipitated salt, isolation of the staurosporine (1) precipitated salt, treatment of the staurosporine (1) isolated salt with an organic base, and isolation of staurosporine (1). Also disclosed are novel polymorphic forms of the mono- and bis-hydrochloride salts of staurosporine (1).

##STR00001##

The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a subject, pharmaceutical composition comprising such compounds, and their use as MCL-1 inhibitors, useful for treating diseases such as cancer.

The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a subject, pharmaceutical composition comprising such compounds, and their use as MCL-1 inhibitors, useful for treating diseases such as cancer.

The present disclosure relates to strapped calixpyrrole compounds, polymer monomers and polymers comprising strapped calixpyrrole substructures, and compositions thereof. Also provided herein are methods of use of said strapped calixpyrrole compounds, polymer monomers, and polymers, such as for the selective extraction of specific salts.

The present invention is directed to compounds of Formula I: ##STR00001##
or a pharmaceutically acceptable salt thereof, wherein the substituents A, R.sup.1, R.sup.2, R.sup.3a, R.sup.3b, R.sup.4a, R.sup.4b and n are as defined herein. The inventions also directed to pharmaceutical compositions comprising the compounds, methods of treatment using the compounds and methods of preparing the compounds.

The present invention is directed to compounds of Formula I: ##STR00001##
or a pharmaceutically acceptable salt thereof, wherein the substituents A, R.sup.1, R.sup.2, R.sup.3a, R.sup.3b, R.sup.4a, R.sup.4b and n are as defined herein. The inventions also directed to pharmaceutical compositions comprising the compounds, methods of treatment using the compounds and methods of preparing the compounds.

The present disclosure relates to certain chiral diaryl macrocyclic derivatives, pharmaceutical compositions containing them, and methods of using them to treat cancer.

The present disclosure relates to certain chiral diaryl macrocyclic derivatives, pharmaceutical compositions containing them, and methods of using them to treat cancer.

Amorphous rifaximin, methods of making it, and pharmaceutical compositions containing it. Also described are methods of converting amorphous rifaximin to crystalline rifaximin and vice versa.

Amorphous rifaximin, methods of making it, and pharmaceutical compositions containing it. Also described are methods of converting amorphous rifaximin to crystalline rifaximin and vice versa.